Extracorporeal shockwave therapy of the perineum for male patients with chronic pelvic pain syndrome : a pilot study
© 2024 The Asian Pacific Prostate Society. Published by Elsevier B.V..
Background: Chronic pelvic pain syndrome (CPPS) is a complex condition that is often difficult to treat and may sometimes require a multidisciplinary team. Among the wide array of treatment options is extracorporeal shockwave therapy (ESWT). However, its role in CPPS remains controversial. The purpose of our study is to assess the efficacy and safety of ESWT of the perineum in male patients with CPPS.
Methods: Fourteen patients aged between 21 and 85 years were recruited in this single-center, single-arm prospective trial from October 2018 to October 2020. ESWT was delivered to the perineum weekly for up to 8 weeks. Assessment was done via International Index for Erectile Function, International Prostate Symptom Score, King's Health Questionnaire, National Institutes of Health - Chronic Prostatitis Symptom Index, Visual Analogue Scale, Analgesic Questionnaire, and UPOINT (urinary symptoms [U], psychosocial dysfunction [P], organ-specific symptoms [O], infection-related symptoms [I], neurological/systemic conditions [N], tenderness of skeletal muscles [T]) phenotype system. The parameters are assessed before the start and end of treatment as well as at regular time points on follow-up appointments up to 20 weeks.
Results: Thirteen patients completed the study. There was improvement in the Visual Analogue Scale pain score, Tenderness domain on UPOINT, King's Health Questionnaire, and National Institutes of Health - Chronic Prostatitis Symptom Index scores. In terms of erectile function, improvement in the erectile function domain of International Index for Erectile Function was observed. There was also significant improvement in lower urinary tract symptoms assessed on International Prostate Symptom Score. There were no adverse events reported post treatment and during the follow-up period.
Conclusions: ESWT improved pain and quality of life of male patients with CPPS. It can be a safe and effective treatment modality in the armamentarium of CPPS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Prostate international - 12(2024), 1 vom: 08. März, Seite 27-34 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Joe K C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic pelvic pain syndrome |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.prnil.2023.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370134753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370134753 | ||
| 003 | DE-627 | ||
| 005 | 20240327000120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.prnil.2023.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370134753 | ||
| 035 | |a (NLM)38523905 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Joe K C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extracorporeal shockwave therapy of the perineum for male patients with chronic pelvic pain syndrome |b a pilot study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Asian Pacific Prostate Society. Published by Elsevier B.V. | ||
| 520 | |a Background: Chronic pelvic pain syndrome (CPPS) is a complex condition that is often difficult to treat and may sometimes require a multidisciplinary team. Among the wide array of treatment options is extracorporeal shockwave therapy (ESWT). However, its role in CPPS remains controversial. The purpose of our study is to assess the efficacy and safety of ESWT of the perineum in male patients with CPPS | ||
| 520 | |a Methods: Fourteen patients aged between 21 and 85 years were recruited in this single-center, single-arm prospective trial from October 2018 to October 2020. ESWT was delivered to the perineum weekly for up to 8 weeks. Assessment was done via International Index for Erectile Function, International Prostate Symptom Score, King's Health Questionnaire, National Institutes of Health - Chronic Prostatitis Symptom Index, Visual Analogue Scale, Analgesic Questionnaire, and UPOINT (urinary symptoms [U], psychosocial dysfunction [P], organ-specific symptoms [O], infection-related symptoms [I], neurological/systemic conditions [N], tenderness of skeletal muscles [T]) phenotype system. The parameters are assessed before the start and end of treatment as well as at regular time points on follow-up appointments up to 20 weeks | ||
| 520 | |a Results: Thirteen patients completed the study. There was improvement in the Visual Analogue Scale pain score, Tenderness domain on UPOINT, King's Health Questionnaire, and National Institutes of Health - Chronic Prostatitis Symptom Index scores. In terms of erectile function, improvement in the erectile function domain of International Index for Erectile Function was observed. There was also significant improvement in lower urinary tract symptoms assessed on International Prostate Symptom Score. There were no adverse events reported post treatment and during the follow-up period | ||
| 520 | |a Conclusions: ESWT improved pain and quality of life of male patients with CPPS. It can be a safe and effective treatment modality in the armamentarium of CPPS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic pelvic pain syndrome | |
| 650 | 4 | |a Extracorporeal shockwave therapy | |
| 650 | 4 | |a Perineum | |
| 650 | 4 | |a Tender point | |
| 650 | 4 | |a Trigger point | |
| 700 | 1 | |a Law, Terence Y X |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Pek, Gregory X W |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Qi Y |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Yi Q |e verfasserin |4 aut | |
| 700 | 1 | |a Chia, Jun Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Man K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Prostate international |d 2013 |g 12(2024), 1 vom: 08. März, Seite 27-34 |w (DE-627)NLM232579903 |x 2287-8882 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:1 |g day:08 |g month:03 |g pages:27-34 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.prnil.2023.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 1 |b 08 |c 03 |h 27-34 | ||